European Platelet Rich Plasma Market Set for Steady Growth, Projected to Reach US$ 80.3 Million by 2033

A recent market study indicates that the Europe Platelet Rich Plasma (PRP) market, valued at over US$ 57.5 million in 2023, is on a trajectory for significant growth, with expectations to ascend to a market valuation of US$ 80.3 million by 2033. This growth trend reflects a stable Compound Annual Growth Rate (CAGR) of 3.4% over the ten-year forecast period.

This notable expansion within the PRP sector is largely driven by enhanced patient-centric strategies employed by healthcare providers across Europe. These strategies focus on increasing patient engagement in treatment decisions and providing detailed education about the benefits and realistic outcomes of PRP therapies.

Sample Report Market Insights: https://www.futuremarketinsights.com/reports/sample/rep-eu-1599

Clinics across the region are making strides in optimizing the patient experience, integrating innovations that allow for more flexible scheduling, quicker recovery periods, and superior post-treatment care. Such improvements are proving instrumental in not only boosting patient satisfaction but also in fostering the sustainable growth of the PRP market.

Europe’s dedication to advancing PRP applications highlights its role as a pivotal player in the global landscape for this therapy. Healthcare practitioners’ commitment to patient involvement and the continuous improvement of service standards are setting a benchmark for excellence in the global PRP market.

“Technological developments, sustainability, and strategic partnerships are driving a shift in the Europe platelet rich plasma (PRP). PRP treatments are becoming smarter thanks to IoT and AI, while regional players and sustainability initiatives are changing the game. PRP is heading toward a more patient- and environmentally-focused future,” Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Key Takeaways:

  • In 2018, the industry size stood at US$ 43.4 million.
  • The industry size expanded at a 4.6% CAGR from 2018 to 2022.
  • In 2022, the industry size stood at US$ 54.93 million.
  • In 2023, the kits segment occupies 78% of Europe’s shares for platelet rich plasma (PRP).
  • In 2023, the knee segment holds 37.0% of Europe’s platelet-rich plasma (PRP) shares.
  • The industry in the United Kingdom will rise at a 2.10% CAGR from 2023 to 2033.
  • In 2023, Germany occupies 18% of Europe’s platelet rich plasma (PRP) shares.

Click Here to Request Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-eu-1599

Competitive Landscape:

Strategic partnerships are gaining traction, with established corporations collaborating with startups, research institutes, and healthcare facilities to increase product innovation.

Research and development is a top priority, with considerable investments made to improve PRP preparation processes and examine novel medicinal uses.

Recent Developments Observed by FMI:

  • ProGen PRP Advantage, now known as ProGen PRP Eclipse, was rebranded by Crown Aesthetics, a division of Crown Laboratories, Inc., in December 2022. ProGen PRP and Eclipse PRP have been combined into a single best-in-class solution as an example of Crown’s unwavering commitment to providing physicians and their patients with market-leading products and technology.
  • The United Kingdom-based pharmaceutical company Ester Medical announced in May 2022 that it had signed an agreement with Aesthetic Management for the long-term marketing and distribution of Eclipse PRP and Tropocells in the United States.

Key Companies Profiled:

  • Arthrex, Inc.
  • Stryker Corporation
  • Johnson and Johnson Ltd.
  • Zimmer Biomet Holdings Inc.
  • Terumo Corporation
  • Glofinn Oy
  • Medira Ltd.
  • Regen Lab S.A.

Key Segments:

By Product Type:

  • Instruments
  • Kits
  • Kits by Type
  • Pure Platelet Rich Plasma (P-PRP)
  • Leukocyte-Rich Platelet Rich Plasma (L-PRP)
  • Leukocyte-Platelet-Rich Fibrin (L-PRF)
  • Pure Platelet Rich Fibrin (P-PRF)
  • Kits by Origin
  • Autologous Platelet Rich Plasma
  • Homologous Platelet Rich Plasma
  • Allogeneic Platelet Rich Plasma

By Application:

  • Knee
  • Elbow
  • Foot and Ankle
  • Shoulder
  • CMF
  • Others

By Country:

  • United Kingdom
  • France
  • Germany
  • Spain
  • Italy
  • Rest of Europe

Request Purchase on Report: https://www.futuremarketinsights.com/checkout/1599

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *